SCHEMBL326998

SCHEMBL326998

CC(C)(C)c1sc(S(=O)(=O)c2cc(Cl)c(F)cc2F)nc1NC(=O)O

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 4/20 0.33
PIK3CG P48736 4/20 0.33
PIK3C3 Q8NEB9 2/20 0.33
PIK3CA P42336 2/20 0.31
PIK3CB P42338 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
IDH1 O75874 1/20 0.31
SGK1 O00141 1/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.30
GPR27 Q9NS67 1/20 0.30
GRM4 Q14833 1/20 0.30
AGTR1 P30556 1/20 0.30
PIK3C2A O00443 1/20 0.30
PIK3C2B O00750 1/20 0.30
PI4KA P42356 1/20 0.30
PRKDC P78527 1/20 0.30
PI4KB Q9UBF8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1094850 0.91 PIK3CD (0.33) PIK3CDPIK3CGPIK3CAPIK3CB
SCHEMBL319961 0.74 SMN1; SMN2 (0.38) PIK3CDPIK3CGPIK3C3SMN1; SMN2IDH1
SCHEMBL29668968 0.69 CNR2 (0.32) SMN1; SMN2SGK1MAPTMAPK1HTT
SCHEMBL16094686 0.66 ALPL (0.35) MAPTHTT
SCHEMBL1745697 0.64 SLC1A3 (0.35) PIK3CDPIK3CGPIK3CAPIK3CBSMN1; SMN2
SCHEMBL20063809 0.60 SCN9A (0.59) SGK1HTT
SCHEMBL327000 0.60 PTPN22 (0.35)
SCHEMBL13646656 0.59 ALDH1A1 (0.33) SGK1
SCHEMBL29641997 0.59 ALDH1A1 (0.33) SGK1
SCHEMBL320432 0.57 TRPV4 (0.41) SGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493448-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-11-15 US disclosed
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
EP-2590972-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2015-01-21 EP disclosed
EP-2590972-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-15 EP disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
WO-2012004706-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO disclosed
EP-2385938-A1 SULFONAMIDE DERIVATIVES Pfizer Limited (GB) 2011-11-16 EP disclosed
US-8040476-B2 Display device and method of producing the same MITSUBISHI ELECTRIC CORPORATION (JP) 2011-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109667-A1 Chemical Compounds SCN1A, SCN7A, SCN1B PIK3CD 1373/4885PIK3CG 1231/4885PIK3C3 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.